<DOC>
	<DOCNO>NCT00754624</DOCNO>
	<brief_summary>Safety Follow-Up Trial PDC-INS-0008 MKC-TI-005</brief_summary>
	<brief_title>An Open-label , Multi-center , International , Three-year , Safety Tolerability 'Follow ' Trial</brief_title>
	<detailed_description>This uncontrolled study without comparator . Subjects follow 4 year Technosphere Insulin . Of 229 subject 199 expose ≥12 mo , 175 ≥ 24 mo , 60 ≥ 36 mo , 31 ≥ 42 mo , &amp; 2 48 mo .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Previous completion PDCINS0008 MKCTI005 Subjects must able attend schedule visit , opinion Investigator , able complete safety trial Subjects must able understand English access validate primary language trial document Written inform consent Drug alcohol dependency Smokers ( subject expect remain nonsmoker throughout participation trial ) Known hypersensitivity trial drug drug similar chemical structure Anemia ( hemoglobin level &lt; 11 g/dL female &lt; 12 g/dL male ) Evidence moderate great ketone urine Women childbearing potential practicing inadequate birth control . ( Adequate birth control define use oral contraceptive , condom diaphragms spermicide , intrauterine device , DepoProvera , contraceptive patch surgical sterilization ) Women pregnant Clinically significant adverse event remain unresolved previous trial and/or clinically significant abnormal laboratory value determine Investigator MKC Medical Monitor unsafe confound continued participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>